Can Hypomethylating Agents Be Used for MPNs?

Published on

Topics include: Emerging Research

What are hypomethylating agents? Can myeloproliferative neoplasm (MPN) patients benefit from them? Leading MPN expert Dr. Guillermo Garcia-Manero, from The University of Texas MD Anderson Cancer Center, joined Patient Power to discuss studies looking at optimizing the use of hypomethylating agents and the future of combination therapies. Watch now to find out more.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.


View more programs featuring and

Related Programs

ASCO 2019: Noted MPN Expert Shares Key Takeaways for Patients

Leading MPN expert Dr. Ruben Mesa gives clinical trial data updates for MPNs and insight to where treatment research is headed. Watch now to learn more.


Prioritizing Patients: Dr. Pemmaraju’s MPN Highlights From ASCO 2019

How are researchers going beyond the breakthroughs in cancer care? Watch as Dr. Naveen Pemmaraju discusses MPN treatment developments from ASCO 2019.


Experts Explain MDM2 Inhibition and Clinical Trial for MPN Patients

How does MDM2 inhibition work to treat MPNs? Watch as experts Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss an upcoming MDM2 inhibitor clinical trial for patients living with MF and PV.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on July 10, 2019